---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-058273"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:48:22.010434+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q4 net loss $25.1M, cash $765.4M; NUV-422 gets Fast Track

## Summary
- Net loss Q4 2021 was $25.1M ($0.12/share) vs $13.3M ($0.11) in Q4 2020.
- Full-year 2021 net loss $86.8M vs $41.7M in 2020; R&D spend $69.0M (up from $32.6M).
- Cash, equivalents, and marketable securities $765.4M as of Dec 31, 2021.
- FDA Fast Track for NUV-422 (high-grade gliomas); IND cleared for NUV-868 (solid tumors).
- Expects Phase 1 safety data for NUV-422 in 2022; multiple pipeline milestones planned.

## SEC filing metadata
- accession: 0001193125-22-058273
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312522058273/0001193125-22-058273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312522058273/d261084d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-058273
- JSON: https://secwatch.observer/filing/0001193125-22-058273.json
- Plain text: https://secwatch.observer/filing/0001193125-22-058273.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.